Publications
(2010 - 2018)
1. Tranmer GGK and Hasinoff BB, Camptothecin (CPT) derivative(S) and methods and uses
thereof. 2018.
2. Liang D, Wu X, Hasinoff BB, Herbert DE and Tranmer GK, Evaluation of Nitrobenzyl
Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia
Targeting Prodrugs. Molecules 23, 2018.
3. Hasinoff
BB and Patel D, Molecular mechanisms of the cardiotoxicity of the
proteasomal-targeted anticancer drugs bortezomib, carfilzomib, ixazomib,
oprozomib, and delanzomib. American
Association for Cancer Research, Chicago April 16, 2018, 2018.
4. Hasinoff
BB, Progress curve analysis of the kinetics of slow-binding anticancer drug
inhibitors of the 20S proteasome. Archives
of Biochemistry and Biophysics 639:
52-58, 2018.
5. Hasinoff
BB, Patel D and Wu X, The myocyte-damaging effects of the BCR-ABL1-targeted
tyrosine kinase inhibitors increase with potency and decrease with specificity.
Cardiovascular Toxicology 17: 297-306, 2017.
6. Hasinoff
BB, Patel D and Wu X, Molecular mechanisms of the cardiotoxicity of the
proteasomal-targeted drugs bortezomib and carfilzomib. Cardiovascular Toxicology 17:
237-250, 2017.
7. Hasinoff
BB and Patel D, Disulfiram is a slow-binding partial noncompetitive
inhibitor of 20S proteasome activity. Archives
of Biochemistry and Biophysics 633:
23-28, 2017.
8. Hasinoff
BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S and Yalowich JC, Finally,
a non-cardiotoxic doxorubicin analog. Canadian
Oxidative Stress Consortium 9,
2016.
9. Hasinoff
BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S and Yalowich JC,
Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase
II targeting agent with cellular selectivity for the topoisomerase IIa isoform.
Journal of Pharmacology and Experimental
Therapeutics 356: 397-409, 2016.
10. Hasinoff
BB, Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted
anticancer drugs bortezomib and carfilzomib. American Association for Cancer Research. New Orleans, April 12, 2016,
2016.
11. Yadav AA, Chee G-L, Wu X, Patel D,
Yalowich JC and Hasinoff BB,
Structure-based design, synthesis and biological testing of piperazine-linked
bis-epipodophyllotoxin etoposide analogs. Bioorganic
& Medicinal Chemistry 23:
3542-3551, 2015.
12. Hasinoff
BB, Wu X, Yadav AA, Patel D, Zhang H, Wang D-S, Chen Z-S and Yalowich JC,
Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and
its complex with Cu(II). Biochemical
Pharmacology 93: 266-276, 2015.
13. Hasinoff
BB, Wu X, Patel D and Yalowich JC, The non-cardiotoxic anticancer drug
pixantrone targets topoisomerase II. American
Association for Cancer Research. Philadelphia, April 20, 2015, 2015.
14. Yadav AA, Wu X, Patel D, Yalowich JC and Hasinoff BB, Structure-based design,
synthesis and biological testing of etoposide analog
epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to
topoisomerase II and DNA. Bioorganic
& Medicinal Chemistry 22:
5935-5949, 2014.
15. Wu X, Yalowich JC, Patel D and Hasinoff BB, Disulfiram is a potent
inhibitor of topoisomerase II. American
Association for Cancer Research, 2014.
16. Herman E, Hasinoff BB, Steiner R and Lipshultz SE, A review of the
preclinical development of dexrazoxane. Progress
in Pediatric Cardiology 36:
33-38, 2014.
17. Hasinoff
BB, Yadav AA, Patel D and Wu X, The cytotoxicity of the anticancer drug
elesclomol is due to oxidative stress indirectly mediated through its complex
with Cu(II). Journal of Inorganic
Biochemistry 137: 22-30, 2014.
18. Hasinoff
BB, Structure-based design, synthesis and biological testing of highly
potent semi-synthetic epipodophyllotoxin-derived hybrid etoposide analogs. American Association for Cancer Research,
2014.
19. Abbott GL, Wu X, Zhao Z, Guo G, Birman
VB, Hasinoff BB and Dmitrienko GI,
Prekinamycin and an isosteric-isoelectronic analogue exhibit comparable
cytotoxicity towards K562 human leukemia cells. Medicinal Chemistry Communications 5: 1364-1370, 2014.
20. Yadav AA, Patel D, Wu X and Hasinoff BB, Molecular mechanisms of
the biological activity of the anticancer drug elesclomol and its complexes
with Cu(II), Ni(II) and Pt(II). Journal
of Inorganic Biochemistry 126:
1-6, 2013.
21. Hasinoff
BB, Yalowich JC, Patel D, Yadav A and Wu C, Molecular mechanisms of
elesclomol cytotoxicity. American
Association for Cancer Research, 2013.
22. Hasinoff
BB, Patel D and Wu X, The dual-targeted HER1/HER2 tyrosine kinase inhibitor
lapatinib strongly potentiates the cardiac myocyte-damaging effects of
doxorubicin. Cardiovascular Toxicology
13: 33-47, 2013.
23. Chee G-L, Brewer AD and Hasinoff BB, Preparation of
2-carbamo(thio)yl-1,3-dioxopropyl derivatives as topoisomerase II targeting
compounds for cancer therapy.
WO2013159224A1, 2013/10/31/, 2013.
24. Chee G and Hasinoff BB, Chemical reactivity and biological activity of
dihydro-1,4-dithiin tetraoxides. Canadian
Journal of Chemistry, 2013.
25. Yalowich JC, Wu X, Zhang R, Kanagasabai
R, Hornbaker M and Hasinoff BB, The
anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as
catalytic inhibitors or poisons of DNA topoisomerase IIa. Biochemical Pharmacology 84:
52-58, 2012.
26. Wu X, Yalowich JC and Hasinoff BB, Elesclomol (STA-4783) is a
potent inhibitor of topoisomerase II. American
Association for Cancer Research, 2012.
27. Nash J, Madec K, Brewer DA, Hasinoff BB and Chee G-L, Chemical
reactivity and biological activity of dihydro-1,4-dithiin tetraoxides. Canadian Society for Pharmaceutical Sciences
Annual Symposium, 2012.
28. Hasinoff
BB, Wu X, Nitiss JL, Kanagasabai R and Yalowich JC, The anticancer
multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase
II. Biochemical Pharmacology 84: 1617-1626, 2012.
29. Hasinoff
BB, Patel D and Wu X, The dual targeted HER1/HER2 tyrosine kinase inhibitor
lapatinib strongly potentiates the cardiac myocyte damaging effects of
doxorubicin. 7th Meeting of the Oxidative
Stress Consortium, 2012.
30. Hasinoff
BB, Patel D and Wu X, Lapatinib and other tyrosine kinase inhibitors
greatly potentiate doxorubicin-induced damage to cardiac myocytes. American Association for Cancer Research,
2012.
31. Chee G-L, Brouwer WG, Osika E, Hasinoff BB and Brewer AD, Preparation
of oxathiazine and dithiine oxides as inhibitors of sulfhydryl-dependent
biomolecules. WO2012024083A1,
2012/02/23/, 2012.
32. Chee G-L, Brouwer WG, Osika E, Hasinoff BB and Brewer AD, Preparation
of oxathiazine and dithiine oxides as inhibitors of sulfhydryl-dependent
biomolecules. US20120142676A1,
2012/06/07/, 2012.
33. Chee G-L, Brouwer WG, Brewer DA, Osika E
and Hasinoff BB, Oxathiazine and
dithiin oxides as inhibitors of sulfhydryl-dependent biomolecules. US Patent
Application 20120142676A1, 27-Jul-2012, 2012.
34. Chee G-L, Brewer DA and Hasinoff BB,
2-Carbamo(thio)yl-1,3-dioxopropyl derivatives in cancer therapy. US Provisional
Application 61/638176, 2012.
35. Chee G-L, Bhattarai B, Gietz RD,
Alrushaid S, Nitiss JL and Hasinoff BB,
Chemical reactivity and microbicidal action of bethoxazin. Bioorganic & Medicinal Chemistry 20: 1494-1501, 2012.
36. Zhang R, Wu X, Yalowich JC and Hasinoff BB, Design, synthesis, and
biological evaluation of a novel series of bisintercalating DNA-binding
piperazine-linked bisanthrapyrazole compounds as anticancer agents. Bioorganic & Medicinal Chemistry 19: 7023-7032, 2011.
37. Wu X, Yalowich JC and Hasinoff BB, The anticancer kinase
inhibitor dovitinib (TKI258) may have multiple modes of action because it also
binds DNA and inhibits topoisomerase I and topoisomerase IIa. American Association for Cancer Research
Abstract no. 2530, 2011.
38. Wu X, Yalowich JC and Hasinoff BB, Cadmium is a catalytic
inhibitor of DNA topoisomerase II. Journal
of Inorganic Biochemistry 105:
833-838, 2011.
39. Herman EH, Knapton A, Rosen E, Thompson
K, Rosenzweig B, Estis J, Agee S, Lu QA, Todd JA, Lipshultz S, Hasinoff BB and Zhang J, A multifaceted
evaluation of imatinib-induced cardiotoxicity in the rat. Toxicologic Pathology 39:
1091-1106, 2011.
40. Hasinoff
BB, Patel D and Wu X, Lapatinib in combination with doxorubicin is highly
damaging to cardiac myocytes. American
Association for Cancer Research Abstract
no. 3576, 2011.
41. Alrushaid S, Bhattaria B, Gietz RG,
Yalowich JC, Nitiss JL, Hasinoff BB
and Chee G, Bethoxazin is a potent inhibitor of DNA topoisomerase II. 2nd Canadian Pharmacy Education and Research
Conference and 68th Association of Faculties of Pharmacy of Canada Annual
General Meeting Abstract # BR-13,
2011.
42. Zhang R, Wu X, Guziec LJ, Guziec F, Jr.,
Chee G-L, Yalowich JC and Hasinoff BB,
Design, synthesis and biological evaluation of a novel series of
anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as
anticancer agents. Bioorganic &
Medicinal Chemistry 18:
3974-3984, 2010.
43. Zhang R, Wu X, Chee G-L, Guziec LJ,
Guziec F, Yalowich JC and Hasinoff BB,
Design, synthesis and biological evaluation of a novel series of
anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as
anticancer agents. American Association
for Cancer Research Abstract # 3509:
342, 2010.
44. Wu X, Zhang R, Guziec L, Guziec F,
Yalowich JC and Hasinoff BB, The
molecular docking-based design and biological evaluation of a novel series of
bisintercalating DNA-binding bisanthrapyrazole compounds containing amine
linkers. American Association for Cancer
Research Abstract # 3510: 342,
2010.
45. O'Hara KA, Dmitrienko GI and Hasinoff BB, Kinamycin F downregulates cyclin
D3 in human leukemia K562 cells. Chemico-Biological
Interactions 184: 396-402, 2010.
46. Hasinoff
BB and Patel D, The lack of target specificity of small molecule anticancer
kinase inhibitors is correlated with their ability to damage myocytes in vitro.
Toxicology and Applied Pharmacology 249: 132-139, 2010.
47. Hasinoff
BB and Patel D, The cardiotoxicity and myocyte damage caused by small
molecule anticancer tyrosine kinase inhibitors is correlated with lack of
target specificity. American Association
for Cancer Research Abstract no.
2602: 283, 2010.
48. Hasinoff
BB and Patel D, Mechanisms of myocyte cytotoxicity induced by the
multikinase inhibitor sorafenib. Cardiovascular
Toxicology 10: 1-8, 2010.
49. Hasinoff
BB, The cardiotoxicity and myocyte damage caused by small molecule
anticancer kinase inhibitors is correlated with their lack of target
specificity. Western Canada Medicinal
Chemistry Workshop 11, 2010.
50. Hasinoff
BB, The cardiotoxicity and myocyte damage caused by small molecule
anticancer kinase inhibitors is correlated with their lack of target
specificity. In: Cardiovascular
Complications in Oncology: Yesterday and Today, Naples, Italy, October2010. The II National Congress of
Cardioncology.
51. Hasinoff
BB, The pharmacology of dexrazoxane: iron chelating prodrug and
topoisomerase II inhibitor. In: Razoxane
and dexrazoxane - two multifunctional agents (Eds. Hellmann K and Rhomberg
W), pp. 158-167. Springer, Dordrecht, 2010.
52. Hasinoff
BB, The cardiotoxicity and myocyte damage caused by small molecule
anticancer tyrosine kinase inhibitors is correlated with lack of target
specificity. Toxicology and Applied
Pharmacology 244: 190-195, 2010.
53. Chee G-L, Yalowich JC and Hasinoff BB, A diazirine-based
photoaffinity etoposide probe for labeling topoisomerase II. American Association for Cancer Research
Abstract no. 3508: 342, 2010.
54. Chee G-L, Yalowich JC, Bodner A, Wu X and
Hasinoff BB, A diazirine-based
photoaffinity etoposide probe for labeling topoisomerase II. Bioorganic & Medicinal Chemistry 18: 830-838, 2010.